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Effective cancer immuno-and virotherapies are hindered by a lack of identified tumor-associated antigens (TAAs), poor coverage of the antigenic repertoire expressed by tumors, and difficulties of vector targeting to tumors in vivo [1] [2] [3] [4] [5] [6] . In studies aimed at inducing direct in vivo immune selection of TAAs, we have shown that killing normal cells in situ with the adjuvant hsp70 generates T cell responses to antigens that mediate rejection of tumors of the same histological type [7] [8] [9] [10] [11] . With this approach 12, 13 , a broad repertoire of individually weak T cell responses is raised against multiple TAAs, imposing a cumulatively strong selective pressure against immune escape, and no tumors have to be accessed by targeted vector delivery. However, injection of cytotoxic vectors into normal tissues often results in toxicity 8, 9 . To alleviate these complications, we reasoned that we could provide a broad antigenic repertoire for in vivo immune selection of relevant TAAs by expressing a cDNA library of a normal tissue from a systemically delivered, immunogenic vector, to activate autoimmune and antitumor T cell responses, thereby dispensing with the need to inject directly into normal tissues. Regarding possible vectors, we hypothesized that viruses such as vesicular stomatitis virus (VSV) could act as potent adjuvants for expression of antigens [14] [15] [16] [17] , including TAAs [18] [19] [20] , provided the TAA-expressing virus can access the draining lymph nodes (DLN) [20] [21] [22] [23] [24] .
Combining these observations, we hypothesized that cDNA from a normal tissue could be expressed from the VSV platform [14] [15] [16] [17] [18] [19] [20] 23 to vaccinate against a wide range of TAAs expressed on tumors of the same histological type. We also exploited the observation that altered self epitopes of TAAs can be more immunogenic than the corresponding self epitopes by activating T cells that are cross reactive against both normal self, and altered self, epitopes [25] [26] [27] . We show here that a virally expressed epitope library (VEEL) from normal human prostate can induce rejection of established mouse prostate tumors, without detectable autoimmunity, probably as a result of the lack of inflammatory signals associated with direct injection of the prostate. Tumors that escaped immune selection adopted a new phenotype and could be treated with a second-line therapy. Therefore, virus-expressed cDNA libraries represent a novel paradigm by which the ability of highly mutable tumor cells to escape selective pressures in vivo can be exploited to therapeutic advantage.
RESULTS

Virally expressed altered-self epitope library
To express a broad repertoire of antigens against which potential antitumor T cell responses might be raised, we cloned a cDNA library from normal human prostate, termed altered self antigen and epitope library (ASEL) into VSV (Fig. 1a) in direct or reverse orientations. ASEL-direct and ASEL-reverse libraries had titers (1 × 10 7 -6 × 10 7 plaque-forming units (PFU) per ml) 1-2 log lower than those of control VSV encoding a green fluorescent protein tag (VSV-GFP).
Gene sequences encoding human prostate antigens, but not the melanocyte-and melanoma-associated TRP-2 (Fig. 1b) , gp100 or tyrosinase antigens (data not shown), were present in the ASELs (Fig. 1b) .
We infected BHK cells with the library to analyze gene expression. Expression of prostate-specific sequences (Fig. 1b) , as well as, in some cases, full-length protein (prostate-specific antigen, PSA), was transferred to target cells by the ASEL virus (Fig. 1c) . Using RT-PCR (Fig. 1d) , we estimated that the positive PSA signal in 1 × 10 5 infected BHK cells derived from infection by about 200 VSV-PSA particles and yielded PSA at tenfold lower levels than are present in 1 × 10 4 LN-Cap human prostate cells (Fig. 1c) , indicating that the library could transfer expression of PSA to target cells.
When we infected H2-K b mouse C57BL/6 splenocytes with VSVencoded cDNA libraries from mouse B16 melanoma cells that either did or did not express chicken ovalbumin (OVA), naive OT-I T cells were activated to secrete interferon-γ (IFN-γ), indicating transfer of expression of the SIINFEKL epitope 28 to the splenocytes at levels similar to infection of the splenocytes with a transgenic VSV expressing OVA (VSV-OVA) at a multiplicity of infection (MOI) of 0.01 (Fig. 1e) . However, using the PCR assay as in Figure 1d , we estimated that the VSV-cDNA(OVA) virus was present in the splenocyte infections at an MOI of about 1 log lower. 41 . Column 9, OT-I activated by SIINFEKL peptide; column 14, OT-I alone (no splenocytes, no VSV). Splenocytes from mice injected intraprostatically with ASEL secreted both IFN-γ ( Fig. 2e) and interleukin-17 (IL-17) (Fig. 2f ) in response to normal mouse prostate cells (data not shown) or TC2 mouse prostate tumor cells (Fig. 2e,f) , but not to mouse B16 melanoma cells (data not shown). In contrast, after 60 d, prostates from mice injected intravenously with ASEL were not substantially different from controls in either weight (Fig. 3a) or histology (data not shown), indicating that the treatment had not induced autoimmune consequences.
Intravenous injection of ASEL cures established tumors
We tested the immunotherapeutic efficacy of ASEL against a mouse prostate tumor TC2. Intravenous ASEL generated a prostate-specific T helper type 17 (T H 17), but not an IFN-γ, response ( conferred greater survival than either intratumoral ASEL (P = 0.01) or intratumoral VSV-GFP (P < 0.0001) (Fig. 3c) . Neither intravenous VSV-GFP (Fig. 3c) nor intravenous ASEL reverse (data not shown) generated a therapeutic response. In contrast, ASEL had no effect against subcutaneous B16 melanomas (Fig. 3d,e) . Similarly, a VSVcDNA library in which the cDNA was cloned from human melanoma cells substantially slowed growth of mouse B16 melanomas, but had no effect against TC2 tumors (Fig. 3d,e) . With more injections of ASEL, tumors were cured more effectively with intravenous, compared to intratumoral, treatment (Fig. 3f) . Thus, nine intravenous injections of ASEL cured over 80% of mice with TC2 tumors, compared to 0% with VSV-GFP (P < 0.0001) or ASEL reverse (data not shown and Fig. 3f) , with no detectable autoimmune prostatitis. Unlike with intravenous treatment (Fig. 3b) , no mice treated intratumorally with ASEL, including three mice that were cured, developed T H 17 (Fig. 3g) or IFN-γ (data not shown) responses to prostate cell lysate. Consistent with an immune, as opposed to oncolytic, mechanism for intravenous ASEL, therapy was dependent upon CD4 + T cells but not CD8 + T cells or natural killer (NK) cells (Fig. 3h) .
Three intravenous injections of ASEL (Fig. 3c-f ) into C57BL/6 TC2-bearing mice typically induced initial tumor regression with subsequent aggressive recurrence. Recurrent TC2 (TC2R) tumors had substantial histological differences from parental TC2 tumors, with extensive interstitial lymphocyte infiltrates (Fig. 4a-d) . Similarly, TC2R tumors had lost, or reduced, expression of mouse homologs of the human RNAs encoding prostate-specific antigens in ASEL (Fig. 4e) , as well as increased expression of N-cadherin, SNAIL and SLUG, associated with an epithelial-mesenchymal-like transition (Fig. 4f) [29] [30] [31] [32] .
Sequential vaccination cures recurrences
We investigated whether combinations of vaccination with different libraries could prevent the problem of tumor recurrence. Virally expressed immune-escape epitope libraries (IEELs), constructed using cDNA from TC2R tumors of mice treated with ASEL (Fig. 5a) , contained sequences of TC2R-characteristic genes (encoding SNAIL and SLUG; data not shown). Upon infection of target BHK cells, IEELs transferred expression of TC2R-expressed N-cadherin (Figs. 4 and 5) .
TC2 tumor-bearing mice treated with ASEL (days 7, 9 and 11) followed by IEEL (days 25, 27 and 29) had no survival advantage over those treated with ASEL alone (data not shown), probably owing to neutralization of the IEEL virus by neutralizing antibodies against VSV raised by the prior injections of ASEL 23 . Consistent with our previous reports that VSV is protected from neutralizing antibodies by loading onto peripheral blood leukocytes at low MOI [21] [22] [23] , we found that immunizing mice against VSV abrogated the therapeutic effect of ASEL, but treatment of VSV-immune, TC2-bearing mice with CD8 + T cells preloaded with ASEL virus, denoted T(ASEL), restored ASEL's efficacy (Fig. 5c) . Therefore, we repeated the sequential ASEL-IEEL treatment with IEEL virus preloaded onto CD8 + T cells, denoted T(IEEL). Four of seven mice treated with ASEL and T(IEEL) developed recurrences, but more slowly than those treated with ASEL alone (Fig. 5d) . The three remaining mice never developed recurrences and were tumor free for over 100 d ( Fig. 5d ; P = 0.001 compared to ASEL). We investigated whether it was possible to achieve antitumor therapy even if neutralizing antibodies against VSV were present in mice before therapy started. For this to occur, we had to preload ASEL onto T cells. However, we still observed tumor recurrences when IEEL was not preloaded onto T cells, as well (Fig. 5e) . Sequential T(ASEL)-T(IEEL) treatment generated long-term cures with only a single recurrence. Starting IEEL at day 20 after tumor cell injection (Fig. 5e) consistently led to more long-term cures than starting at day 27 (Fig. 5d) . The sequence of vaccination was also crucial, as neither T(IEEL) nor IEEL alone delayed growth of TC2 tumors (Fig. 5e) .
Long-term survivors of ASEL-IEEL treatment (Fig. 5d,e) developed a prostate-specific T H 17 response against TC2 and normal prostate cells, but not against TC2R cells (Fig. 5f) . Conversely, splenocytes from survivors did not secrete IFN-γ in response to TC2 or normal prostate cells, but consistently produced IFN-γ in response to TC2R tumors (Fig. 5g) . In contrast, nonsurvivors of ASEL-IEEL treatment did not secrete IFN-γ in response to TC2R tumor cell lysates (Fig. 5i) . Over two separate experiments, 7 of 14 mice (50%) treated with ASEL followed by T(IEEL) as in Figure 5d were cured long term, compared to no cures (0%) from treatment with ASEL alone. In contrast, 0 of 14 mice (0%) treated with ASEL followed by IEEL, but also with CD8 + T cell depletion (days 34 and 35), were cured (data not shown). Taken together, these data show that, whereas rejection of TC2 tumors is associated with CD4 + T cells and a T H 17 response, sequential rejection of TC2R tumors is associated with a T H 1-like IFN-γ response mediated by CD8 + T cells.
Altered-self libraries protect better than self libraries
Finally, to investigate the contribution of responses against xenogeneic proteins, we constructed the self epitope expressed library (SEL) using cDNAs from normal mouse prostate. ASEL conferred significantly better protection against TC2 than SEL (P = 0.04), although both ASEL and SEL were better than PBS (P = 0.0064, SEL compared with PBS) or VSV-GFP (P = 0.0029, SEL compared with VSV-GFP) (Fig. 6a) . Similarly, in vitro stimulation via infection of splenocytes with SEL induced lower levels of T H 17 against prostate targets, compared to infection with ASEL ( Fig. 6b-e) . Therefore, altered self libraries induced more potent antiprostate immune responses than libraries encoding purely self proteins.
DISCUSSION
We show here that cDNA libraries transferred into VSV express tissue-specific sequences and proteins and can induce antigen specific immune responses. Using human prostate cDNA to express altered self epitopes 25, 26, 33 , we generated a virus expressing an ASEL. Intraprostatic ASEL injection induced T H 17 and IFN-γ responses against prostate antigens, which were probably responsible for the associated prostatitis 9, 34 . In contrast, intravenous ASEL induced only T H 17, and not IFN-γ, responses to prostate antigens, with no overt signs of prostatitis 9, 34 , probably because the inflammatory signals that intraprostatic injection induces in the prostate were not present with intravenous injection.
Upon repeated intravenous injections of ASEL, we observed both a T H 17 response against prostate antigens and cures of established TC2 tumors mediated by CD4 + T cells. We speculate that a response involving CD4 + and T H 17 cells was responsible for these cures, although further depletion studies are required to confirm this. We believe that the direct oncolytic activity of VSV may have contributed to, but was not responsible for, these cures, because intravenous VSV-GFP had no similar efficacy, and intratumoral ASEL was less effective against TC2 tumors than intravenous injection. This is probably because intravenous injection of virus allows better access to the lymph nodes for cross-priming of antigen-presenting cells.
Emergence of treatment-resistant tumor variants is of great clinical importance [1] [2] [3] 6 . When vaccination was insufficient to clear tumors, rapid regrowth of aggressive recurrent TC2R tumors was observed. TC2R tumors also expressed genes associated with an epithelial-tomesenchymal-type transition [29] [30] [31] [32] . We showed that, early during the immune-driven evolution of TC2 to TC2R tumors, ASEL-treated mice could be vaccinated against the emergence of aggressive TC2R tumors using virus-expressed IEEL, which transferred expression of TC2R's characteristic genes, as opposed to those of TC2. Preloading onto T cells was used to protect IEEL viruses from neutralizing antibodies [21] [22] [23] 35, 36 . Efficacy depended on the sequence in which the libraries were given, on early treatment with IEEL, and probably on the development of two distinct but synergistic immune reactivities differing in antigen specificity and effector phenotypes. The first ASEL-primed response (T H 17-associated, CD4-dependent, TC2-and prostate-specific, TC2R-'blind') forced TC2 tumors to evolve into a phenotype in which the second, IEEL-primed response (IFN-γ-associated, CD8-dependent, prostate-'blind' , TC2R-specific) could clear recurrent tumors as they emerged.
We observed poorer protection with SEL (self antigens) compared to ASEL (xenogeneic, altered self antigens) and weaker stimulation of splenocytes against prostate targets by SEL in vitro. Notably, ASEL protected mice against TC2 tumors, but not B16 melanomas, and ASEL did not stimulate splenocyte reactivity against non-prostate targets. This suggests that immune reactivity generated by ASEL is directed not simply against xenogeneic household proteins (expressed on both B16 cells and normal pancreas) but against lineage-specific antigens-possibly reflecting a difference in the amounts of T cell precursors to these two classes of antigens that survive both thymic and peripheral selection. In contrast, given that xenogeneic antigens associated with rejection of allogeneic transplants include minor histocompatibility antigens (which are not lineage specific), the antigenic targets that lead to rejection of TC2 tumors may turn out to be expressed more widely than simply in the prostate. In summary, we show here that it is possible to vaccinate mice against established tumors using a wide repertoire of self 7, 13 or near-self 25, 26, 33 epitopes encoded by a cDNA library expressed from the platform of a highly immunogenic virus. This allows for in vivo immune selection of TAAs relevant for tumor rejection, without requiring their identification. In addition, systemic delivery of VSV-based libraries in mice is possible, prevents damage inherent in delivering vectors directly to normal tissues 8, 9 and does not induce autoimmunity. Therefore, virus-expressed cDNA libraries from normal tissues of either human (true self) or xenogenic (altered self) origins can be readily constructed for off-the-shelf use and can be easily delivered systemically in vectors amenable to production at clinical grade, thereby representing a new, readily translatable therapy with considerable potential as an antitumor agent.
METhODS
Methods and any associated references are available in the online version of the paper at http://www.nature.com/naturemedicine/.
